VITA 34 International AG presents report for the 1st quarter of 2007 – Strong growth in all areas
Vita 34 International AG / Quarter Results
Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Leipzig, April 27, 2007 - VITA 34 International AG (ISIN DE000A0BL849),
parent company of VITA 34, the leading private umbilical cord blood bank in
the German-speaking countries, has presented its quarterly report for the
1st quarter of 2007. Revenues from continuing operations increased to 3.5
million Euro from 2.6 million Euro in the comparative period in the
previous year. This amounts to an increase of 35 percent. With 2,446
contracts for the storage of cord blood stem cell transplants, 83 percent
more than this period in the previous year, a new quarterly record has been
achieved. The storages run ahead of revenues by around 6 weeks on average.
Earnings before income and tax, EBIT, amounted to 0.3 million Euro, as
opposed to a balanced EBIT in the comparative period last year. After
income tax, there was a surplus of 101,000 Euro in continuing operations,
while there had been a loss of 54,000 Euro in the same period last year.
VITA 34’s equity capital rose as of 31/3/2007 to 22.4 million Euro, not
least due to its successful IPO at the end of March. It had been 12.9
million Euro at the end of 2006. Thus, VITA 34 had an equity ratio of 65
percent at the end of the quarter.
Management believe these healthier than expected quarterly figures are
resulting from the initial effects of the new marketing and sales strategy
and a one-off effect from the PR work in the wake of an important
scientific publication of the first successful use of a leukaemia patient’s
own umbilical cord blood. Growth in revenues and storages of 20 percent is
expected for the year as a whole. The company will develop its sales and
marketing areas even further in the future by using funds from the stock
market flotation in order to accelerate the increase in market potential
for umbilical cord blood banking in Germany.
The quarterly report is now available in its entirety at www.vita34.de in
the 'Investor Relations' section.
Press/Investor Relations:
Axel Mühlhaus Dr. Sönke Knop
edicto GmbH
Zeißelstraße 19
D-60318 Frankfurt
Tel.: +49 (069) 90550552
Fax: +49 (069) 90550577
E-mail: vita34@edicto.de
DGAP 30.04.2007
----------------------------------------------------------------------
Language: English
Issuer: Vita 34 International AG
Deutscher Platz 5a
04103 Leipzig Deutschland
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: info@vita34.de
www: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Indices:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin-Bremen, Düsseldorf, Hamburg, München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
